Russian Covid vaccine over 91 per cent effective trial results suggest RUSSIA S Covid vaccine is 91.6 per cent effective against symptomatic coronavirus, interim trial results suggest. No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at the injection site and weakness or low energy. Interim data from the phase three trial of the Covid-19 vaccine from Russia, Gam-COVID-Vac (Sputnik V), suggests a two-dose regimen of the vaccine offers 91.6 per cent efficacy. The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three quarters of whom received the vaccine and one quarter received a placebo.
Quarantine hotel plans to be revealed this week amid crack down on Covid variant MORE clarity on plans for hotel quarantine will be announced by the Health Secretary within the week, a minister has said, as parts of the country rollout emergency testing to tackle a Covid variant. Universities minister Michelle Donelan said Matt Hancock would be updating Parliament “within the week” on plans around hotel quarantine. Asked what the reason is for a delay in bringing the policy in, she told BBC Breakfast: “I don’t think there’s a delay. There wasn’t a timeframe set originally as to when we would announce this.